Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FKBP5 and resistant attachment predict cortisol reactivity in infants: gene-environment interaction.

Psychoneuroendocrinology·2010
Same author

Common genetic determinants of vitamin D insufficiency: a genome-wide association study.

Lancet (London, England)·2010
Same author

Heart failure and incident late-life depression.

Journal of the American Geriatrics Society·2010
Same author

Maternal thyroid function during early pregnancy and cognitive functioning in early childhood: the generation R study.

The Journal of clinical endocrinology and metabolism·2010
Same author

Predicting survival and morbidity-free survival to very old age.

Age (Dordrecht, Netherlands)·2010
Same author

Serum C reactive protein levels and genetic variation in the CRP gene are not associated with the prevalence, incidence or progression of osteoarthritis independent of body mass index.

Annals of the rheumatic diseases·2010
Same journal

Metastasis of Nasopharyngeal Squamous Cell Carcinoma to the Angle.

Ophthalmology·2026
Same journal

Endocrine Mucin-Producing Sweat Gland Carcinoma of Eyelid.

Ophthalmology·2026
Same journal

Multimodal Imaging of Optic Nerve Invasion in Unilateral Retinoblastoma.

Ophthalmology·2026
Same journal

Avacincaptad Pegol Slows Progressive Ellipsoid Zone Degradation/Loss in Eyes With Geographic Atrophy.

Ophthalmology·2026
Same journal

Access to Intravitreal Anti-VEGF Drugs in Persons with Medicare Advantage Compared with Medicare Fee-For-Service.

Ophthalmology·2026
Same journal

Re: Dones et al.: Emergency department use of ocular point-of-care ultrasound and its utility in diagnosis at a tertiary academic medical center (Ophthalmology. 2026;133:720-727).

Ophthalmology·2026
See all related articles

Related Experiment Videos

Topical beta-blockers and mortality.

Rogier P H M Müskens1, Roger C W Wolfs, Jacqueline C M Witteman

  • 1Department of Ophthalmology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Ophthalmology
|September 20, 2008
PubMed
Summary
This summary is machine-generated.

Topical beta-blocker use, whether long-term or short-term, does not appear to increase the risk of death. This study found no significant association between these medications and increased all-cause or cardiovascular mortality.

Related Experiment Videos

Area of Science:

  • Ophthalmology
  • Cardiology
  • Gerontology

Background:

  • Topical beta-blockers are commonly prescribed for glaucoma.
  • Potential systemic absorption and associated mortality risks are a concern.

Purpose of the Study:

  • To investigate the association between long-term and short-term topical beta-blocker use and mortality.
  • To determine if topical beta-blocker use is linked to increased all-cause or cardiovascular mortality.

Main Methods:

  • A prospective, population-based cohort study (Rotterdam Study) was conducted.
  • Long-term effects were assessed using Cox regression in 3842 participants (aged ≥55).
  • Short-term effects were evaluated by comparing mortality within 3 months between 484 incident users and 4700 age-matched controls.

Main Results:

  • Long-term use showed no significant association with all-cause (HR 0.94; 95% CI, 0.71-1.25) or cardiovascular mortality (HR 1.02; 95% CI, 0.56-1.86).
  • Short-term use revealed similar mortality rates between incident users (0.8%) and controls (1.4%; P=0.31).

Conclusions:

  • Topical beta-blocker use does not appear to be associated with excess mortality.
  • Findings suggest a favorable safety profile regarding mortality for topical beta-blockers.